Roscovitine (Seliciclib, CYC202): A Selective CDK2 Inhibitor for Cancer Research

Executive Summary: Roscovitine (Seliciclib, CYC202) is a highly selective inhibitor of cyclin-dependent kinases (CDKs), with submicromolar IC₅₀ values for CDK2/cyclin E, CDK5/p35, CDK7/cyclin H, and CDC2/cyclin B (A1723, APExBIO). It robustly arrests the cell cycle in late prophase, as demonstrated in diverse eukaryotic models (Wang et al., 2025). Roscovitine significantly inhibits tumor growth in athymic nude mice bearing A4573 tumors (doi:10.1016/j.canlet.2025.217935). It is insoluble in water but highly soluble in DMSO (≥17.72 mg/mL) and ethanol (≥53.5 mg/mL) (A1723, APExBIO). Roscovitine is widely used in studies of cell cycle regulation, apoptosis, and translational cancer biology (Cell Staining Kit, 2024).

Biological Rationale

Cyclin-dependent kinases (CDKs) are serine/threonine kinases that regulate cell cycle progression, transcription, and DNA repair. Aberrant CDK activity is a hallmark of many human cancers, resulting in unchecked proliferation and genomic instability (Wang et al., 2025). Inhibiting CDKs—particularly CDK2, CDK5, CDK7, and CDC2—can arrest cell cycling and trigger apoptosis, making these kinases central targets in cancer research. Roscovitine (Seliciclib, CYC202) was developed as a potent, selective small-molecule inhibitor to interrogate CDK signaling and its consequences on tumor growth. Its use enables researchers to model mechanisms of cell cycle arrest, study resistance to checkpoint inhibitors, and evaluate combinatorial strategies with radiotherapy and immunotherapy (doi:10.1016/j.canlet.2025.217935).

Mechanism of Action of Roscovitine (Seliciclib, CYC202)

Roscovitine (Seliciclib, CYC202) acts as a competitive ATP-binding site inhibitor for a subset of cyclin-dependent kinases. Its primary targets and associated IC₅₀ values (in vitro kinase assays, 25°C, ATP at Km) are:

• CDK2/cyclin E: 0.1 μM
• CDK5/p35: 0.16 μM
• CDK7/cyclin H: 0.49 μM
• CDC2/cyclin B: 0.65 μM

At higher concentrations, roscovitine inhibits ERK1 (IC₅₀ = 34 μM) and ERK2 (IC₅₀ = 14 μM), but these off-target effects require >20 μM, well above typical experimental concentrations (APExBIO). Roscovitine blocks the prophase/metaphase transition, leading to cell cycle arrest in late prophase. This has been demonstrated in Xenopus oocytes, starfish oocytes, and sea urchin embryos (Wang et al., 2025). CDK2 inhibition is directly linked to disruption of DNA synthesis and cell division, underpinning its anti-proliferative effects in cancer models.

Evidence & Benchmarks

• Roscovitine inhibits CDK2/cyclin E kinase activity with an IC₅₀ of 0.1 μM in vitro (APExBIO product page).
• It induces cell cycle arrest at late prophase in Xenopus oocytes and other model systems (Wang et al., 2025, doi:10.1016/j.canlet.2025.217935).
• In vivo, roscovitine reduces tumor volume in athymic nude mice bearing A4573 tumors by a statistically significant margin compared to controls (Wang et al., 2025, doi:10.1016/j.canlet.2025.217935).
• Roscovitine is insoluble in water but dissolves in DMSO at ≥17.72 mg/mL and ethanol at ≥53.5 mg/mL (APExBIO A1723 specification).
• Warming and ultrasonic agitation are recommended for optimal solubilization; solutions should be prepared fresh or stored short-term at -20°C (APExBIO A1723 handling instructions).
• Roscovitine demonstrates selectivity, with 10–100x weaker inhibition of ERK1/2 than its primary CDK targets (APExBIO data sheet).
• For live cell and tumor biology workflows, Roscovitine (SKU A1723) enables reproducible cell cycle arrest and mechanistic studies (see Cell Staining Kit article for scenario-based deployment guidance).

Applications, Limits & Misconceptions

Applications: Roscovitine (Seliciclib, CYC202) is used to:

• Dissect the cyclin-dependent kinase signaling pathway in cancer biology research.
• Model cell cycle arrest and apoptosis in vitro and in vivo.
• Investigate mechanisms of resistance to immunotherapy, especially in the context of PD-1 and TIGIT blockade (Wang et al., 2025).
• Enable combinatorial studies with radiotherapy and checkpoint inhibitors.

Limits: Roscovitine's selectivity is dose-dependent; off-target ERK1/2 inhibition occurs only at concentrations >10 μM. It is not effective against all CDK isoforms, nor is it a pan-kinase inhibitor. Its in vivo efficacy has been demonstrated in specific tumor models (e.g., A4573 in athymic nude mice) but may not translate to all cancer types. Long-term solution storage leads to degradation and loss of potency.

Common Pitfalls or Misconceptions

• Assuming Roscovitine is a pan-CDK inhibitor—it is selective for CDK2, CDK5, CDK7, and CDC2 at submicromolar concentrations.
• Expecting efficacy in water-based solvents—Roscovitine is insoluble in water and must be dissolved in DMSO or ethanol.
• Using high concentrations without accounting for ERK1/2 inhibition—off-target effects emerge above 10 μM.
• Assuming universal tumor efficacy—results are model-dependent and require validation in each new system.
• Long-term storage of working solutions—leads to compound degradation; fresh preparation is recommended.

Workflow Integration & Parameters

Roscovitine (Seliciclib, CYC202) is supplied as a solid by APExBIO (SKU A1723). It should be stored at -20°C. For experimental use, dissolve in DMSO or ethanol to the desired concentration (stock: DMSO ≥17.72 mg/mL; ethanol ≥53.5 mg/mL). Warming to room temperature and brief ultrasonic agitation can improve solubilization. Avoid repeated freeze-thaw cycles. Use freshly prepared solutions for optimal results. Roscovitine's selectivity profile and handling requirements are discussed in detail in this guide, which this dossier extends by providing updated quantitative benchmarks and workflow best practices.

For live cell assays, concentrations in the range of 0.1–10 μM are standard, with exposure times and washout protocols tailored to the specific cell type and readout. In vivo, dosing regimens and schedules must be optimized for each tumor model. For further scenario-based guidance, see this article, which is complemented here with new in vivo efficacy data and solubility parameters.

Conclusion & Outlook

Roscovitine (Seliciclib, CYC202) is a validated, selective CDK inhibitor that empowers mechanistic studies of cell cycle regulation and tumor biology. Its robust arrest of the cell cycle in late prophase and its ability to suppress tumor growth in vivo make it a key tool for cancer research. As immuno-oncology and combination therapies advance, precise cell cycle targeting with agents like Roscovitine will remain central to both mechanistic and translational workflows. For a deeper dive into its role in translational models and next-generation combination therapies, compare this dossier to this perspective, which is now updated with the latest in vivo and workflow data.

Product details, technical documentation, and purchasing information are available at the official APExBIO product page for Roscovitine (Seliciclib, CYC202; SKU A1723).